Market Overview

UPDATE: Credit Suisse Upgrades Dr. Reddy's Laboratories Limited to Outperform on Metropol Market Share

Related RDY
Dr. Reddy's Receives FDA Tentative Approval For Zenavod Capsules
Dr. Reddy's Receives FDA Tentative Approval for Zenavod Capsules, 40 mg for Treatment of Rosacea in Adults
Dr. Reddy's Laboratories' (RDY) Management Discusses on Q3 2016 Results - Earnings Call Transcript (Seeking Alpha)

Credit Suisse raised its rating on Dr. Reddy's Laboratories Limited (NYSE: RDY) from Neutral to Outperform.

Credit Suisse said, "Our positive stance on Dr. Reddy's is driven by a strong pick-up in US sales in the coming quarters. Dr. Reddy's market share on Metoprolol has increased to 15% vs. expectation of 8-10%. Metoprolol market size is large at US$450 mn and is a high-margin product. Our interactions with Intas and Cadila suggested that Metoprolol approval for them is not a near-term event and therefore for at least the next six months Dr. Reddy's should continue to enjoy a high market share on Metoprolol."

Dr. Reddy's Laboratories Limited closed at $34.25 on Wednesday.

Latest Ratings for RDY

Feb 2016CLSAUpgradesUnderperformBuy
Dec 2015Deutsche BankInitiates Coverage onSell
Feb 2013Bank of AmericaDowngradesBuyNeutral

View More Analyst Ratings for RDY
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Upgrades Intraday Update Analyst Ratings


Related Articles (RDY)

Get Benzinga's Newsletters